Caden Capital Partners LP Has $48.01 Million Stock Position in Danaher Co. (NYSE:DHR)

Caden Capital Partners LP lifted its holdings in shares of Danaher Co. (NYSE:DHR - Free Report) by 79.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 209,149 shares of the conglomerate's stock after purchasing an additional 92,795 shares during the quarter. Danaher accounts for 14.6% of Caden Capital Partners LP's holdings, making the stock its 2nd largest position. Caden Capital Partners LP's holdings in Danaher were worth $48,010,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the business. Gilbert & Cook Inc. boosted its holdings in Danaher by 2.5% in the 4th quarter. Gilbert & Cook Inc. now owns 1,749 shares of the conglomerate's stock worth $401,000 after acquiring an additional 42 shares during the period. Grimes & Company Inc. raised its position in shares of Danaher by 0.6% during the 4th quarter. Grimes & Company Inc. now owns 7,390 shares of the conglomerate's stock valued at $1,696,000 after acquiring an additional 43 shares in the last quarter. Dakota Community Bank & Trust NA raised its position in shares of Danaher by 16.4% during the 4th quarter. Dakota Community Bank & Trust NA now owns 320 shares of the conglomerate's stock valued at $73,000 after acquiring an additional 45 shares in the last quarter. Howard Capital Management Group LLC raised its position in shares of Danaher by 4.1% during the 3rd quarter. Howard Capital Management Group LLC now owns 1,229 shares of the conglomerate's stock valued at $342,000 after acquiring an additional 48 shares in the last quarter. Finally, Spinnaker Trust boosted its holdings in shares of Danaher by 1.2% during the fourth quarter. Spinnaker Trust now owns 4,304 shares of the conglomerate's stock valued at $988,000 after acquiring an additional 50 shares during the period. 79.05% of the stock is owned by institutional investors.

Danaher Price Performance

Shares of NYSE:DHR traded up $0.39 on Wednesday, hitting $199.32. The company's stock had a trading volume of 3,729,138 shares, compared to its average volume of 3,359,986. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.40 and a quick ratio of 1.05. The company has a market capitalization of $142.65 billion, a PE ratio of 37.75, a PEG ratio of 2.66 and a beta of 0.86. The company has a 50-day simple moving average of $200.30 and a 200 day simple moving average of $223.12. Danaher Co. has a 1 year low of $171.00 and a 1 year high of $281.70.

Danaher (NYSE:DHR - Get Free Report) last posted its quarterly earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.62 by $0.26. Danaher had a return on equity of 10.82% and a net margin of 16.33%. The business had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.58 billion. Sell-side analysts forecast that Danaher Co. will post 7.63 EPS for the current fiscal year.

Danaher Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, April 25th. Shareholders of record on Friday, March 28th were issued a $0.32 dividend. This is a positive change from Danaher's previous quarterly dividend of $0.27. The ex-dividend date was Friday, March 28th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.64%. Danaher's dividend payout ratio (DPR) is presently 24.85%.

Analysts Set New Price Targets

Several equities analysts have commented on the stock. Guggenheim reissued a "buy" rating and set a $250.00 target price on shares of Danaher in a research note on Wednesday, April 23rd. Robert W. Baird lowered their price objective on shares of Danaher from $231.00 to $225.00 and set an "outperform" rating on the stock in a research note on Wednesday, April 23rd. Stifel Nicolaus raised shares of Danaher from a "hold" rating to a "buy" rating and set a $260.00 target price on the stock in a research report on Friday, March 14th. Jefferies Financial Group decreased their price target on shares of Danaher from $260.00 to $230.00 and set a "buy" rating for the company in a report on Tuesday, April 22nd. Finally, UBS Group decreased their price target on shares of Danaher from $275.00 to $240.00 and set a "buy" rating for the company in a report on Wednesday, April 23rd. Five equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat, Danaher currently has a consensus rating of "Moderate Buy" and an average target price of $264.40.

Insider Buying and Selling

In related news, SVP Brian W. Ellis sold 5,700 shares of Danaher stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the transaction, the senior vice president now directly owns 20,230 shares in the company, valued at approximately $4,534,149.90. The trade was a 21.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 11.10% of the stock is currently owned by corporate insiders.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.